T1	Participants 52 78	superficial bladder cancer
T2	Participants 323 419	patients with primary or recurrent superficial bladder tumors, including carcinoma in situ (CIS)
T3	Participants 772 922	Reported are the incidence of side effects in 165 patients and the recurrence rate of tumors in 308 patients after a follow-up period of twelve months
